PraveenKumarTumulaMD

Oncology • Amarillo, TX

Physician

Join to view full profile

Dr. Tumula is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tumula's full profile

Already have an account?

Office
1826 Point West Pkwy
Amarillo, TX 79124
Phone+1 806-358-8654

Fax+1 806-356-8687

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Hackensack University Medical Center (Mountainside)Residency, Internal Medicine, 2008 - 2011
Rangaraya Medical College NTRClass of 2002

Certifications & Licensure

TX State Medical License 2011 - 2025
MA State Medical License 2014 - 2017
NJ State Medical License 2009 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

748 citations
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhi...
Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard
Clinical Cancer Research. 2013-01-01
390 citations
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers, Jing Wang, Monique B. Nilsson, Junya Fujimoto, Pierre Saintigny
Cancer Discovery. 2012-09-01
31 citations
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01

Press Mentions

Cancer Deaths in U.S. Sees Drop Across the BoardJanuary 29th, 2020